Regeneron

Category

Trial Site Operation in San Antonio Reports Positive Momentum for Regeneron Monoclonal Antibody REGN-COV-2

TrialSite has reported that Lilly's monoclonal antibody (LY-CoV555) evidenced promise at a trial site location in southern Texas and that shortly thereafter recent interim analysis data from Lilly backed that observation. Now Regeneron’s monoclonal antibody cocktail...

Oxford RECOVERY Trial Investigates Regeneron’s REGN-COV2: Will it Reduce Mortality, Hospital Stay & Need for Ventilation?

The prominent global RECOVERY (Randomized Evaluation of COVid-19 thERapY) is one of the world’s largest randomized clinical trials of potential COVID-19 treatments. It was this study that discovered the benefit of dexamethasone in severe COVID-19 cases. The University...

Sioux Falls-based Avera Health Joins REGN-COV2 Clinical Trials Investigating Powerful Monoclonal Antibodies Targeting COVID-19

Regeneron has selected a Sioux Falls-based health care system called Avera Health as a Phase 2 and 3 trial site for the ongoing lab-produced monoclonal antibody combination, known as REGN-COV2, targeting COVID-19. Avera Health, a fully integrated health system...

University of Iowa Hospitals and Clinics Activated as Site for REGN-COV2 Clinical Trial Targeting COVID-19

Clinical investigators at University of Iowa Hospitals and Clinics (UIHC) are participating in a Phase 3 clinical trial investigating Regeneron’s novel monoclonal antibody targeting COVDI-19 known as REGN-COV2. TrialSite News recently showcased this rapidly developed...

University of Buffalo Commences Sarilumab Clinical Trial for those COVID-19 Patients at Risk for Cytokine Storm

University of Buffalo (UB) and Roswell Park Comprehensive Cancer Center received the greenlight from the U.S. Food and Drug Administration to initial a “collaborative clinical study” using sarilumab to address some adverse COVID-19 effects.  The study’s principal...

Regeneron Leverages its Technology Platform, Process and People in the Hopes of Having A COVID-19 Therapy in Trials by Summer

Regeneron and its “VELOCISUITE®” platform was used to develop a treatment for Ebola (REGN-EB3), currently used by the Congolese government to fight that horrific virus. The New York State-based venture has, like many biopharma companies, dedicated a full force...

Pin It on Pinterest